CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: GlobeNewswire
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab demonstrates synergy with standard-of-care therapies, supports plan for prospective combination study VANCOUVER, Washington, March 24, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced the presentation of new preclinical and translational data supporting the potential role of CCR5 inhibition in glioblastoma multiforme (GBM) at AACR Special Conference in Cancer Research: Brain Cancer, held March 23-25, in Philadelphia. Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor survival and limited effective trea
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab [Yahoo! Finance]Yahoo! Finance
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of LeronlimabGlobeNewswire
- Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relapsed/Refractory Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology ConferenceGlobeNewswire
- Former West Coast biotech CEO imprisoned for pocketing millions [Yahoo! Finance]Yahoo! Finance
CYDY
Sec Filings
- 3/25/26 - Form 424B3
- 3/24/26 - Form 4
- 3/24/26 - Form 4
- CYDY's page on the SEC website